New hope for tough brain tumors: immune system drugs tested
NCT ID NCT02648997
Summary
This study is testing whether two immunotherapy drugs, nivolumab alone or combined with ipilimumab, can help control recurrent meningioma brain tumors. It involves 40 adults whose tumors have returned or progressed after prior treatments like surgery or radiation. The main goal is to see if these treatments can stop tumor growth for at least six months by helping the body's own immune system fight the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.